We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shire | LSE:SHP | London | Ordinary Share | JE00B2QKY057 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4,690.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
By Rory Gallivan
LONDON-- Drug company Shire PLC (SHP.LN) Thursday said Phase 3 testing of its Lanadelumab treatment showed a significant reduction in attacks of hereditary angiodema, a rare genetic condition.
Shire will now use the data for its application for approval in the U.S., which it expects to file towards the end of this year or early in 2018.
Shares at 1107 GMT, up 173 pence, or 3.7%, at 4904 pence valuing the company at GBP44.7 billion.
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan
(END) Dow Jones Newswires
May 18, 2017 07:28 ET (11:28 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Shire Chart |
1 Month Shire Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions